本帖最后由 老马 于 2013-3-13 13:43 编辑
. v, K& C5 h" I. O5 o6 a0 D
( \6 S5 i2 P0 M/ `2 e4 }( ~健择(吉西他滨)+顺铂+阿瓦斯汀# A* X2 u0 c* j# O$ C3 Y& U
Gemzar +Cisplatin + Avastin* x) B- y' e ]; j
http://annonc.oxfordjournals.org/content/21/9/1804.full
4 Z) y, z* l/ b; m3 z$ cOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
: C: X0 S) t' o9 OPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
; n4 y! q* v$ \9 ^7 pResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. ( B# w: W$ U! \7 z2 s" X
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 833)
- _- u4 w" }* p- c( w& }! z
华为网盘附件:
9 m, C ?' V' K' {( v* C【华为网盘】ava.JPG
' N4 H- P$ T' w% e R/ I |